Display options
Cite
Slim A, Castillo-Rojas L, Hulten E, et al. Rosiglitazone and fenofibrate additive effects on lipids. Cholesterol. 2011;2011:286875doi: 10.1155/2011/286875.
Slim, A., Castillo-Rojas, L., Hulten, E., Slim, J. N., Pearce Moore, D., & Villines, T. C. (2011). Rosiglitazone and fenofibrate additive effects on lipids. Cholesterol, 2011286875. https://doi.org/10.1155/2011/286875
Slim, Ahmad, et al. "Rosiglitazone and fenofibrate additive effects on lipids." Cholesterol vol. 2011 (2011): 286875. doi: https://doi.org/10.1155/2011/286875
Slim A, Castillo-Rojas L, Hulten E, Slim JN, Pearce Moore D, Villines TC. Rosiglitazone and fenofibrate additive effects on lipids. Cholesterol. 2011;2011:286875. doi: 10.1155/2011/286875. Epub 2011 Nov 24. PMID: 22162805; PMCID: PMC3227227.
Copy Download .nbib Format: NLM
Share it on

Cholesterol. 2011;2011:286875. doi: 10.1155/2011/286875. Epub 2011 Nov 24.

Rosiglitazone and fenofibrate additive effects on lipids.

Cholesterol

Ahmad Slim, Laudino Castillo-Rojas, Eddie Hulten, Jennifer N Slim, Dorette Pearce Moore, Todd C Villines

Affiliations

  1. Cardiology Service, Brooke Army Medical Center, San Antonio, TX 78234-6200, USA.

PMID: 22162805 PMCID: PMC3227227 DOI: 10.1155/2011/286875

Abstract

Background. To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults. Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenofibrate + placebo, rosiglitazone + fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone/fenofibrate groups compared with placebo (P = 0.0496). However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo (P = 0.009). There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone/fenofibrate groups (P = 0.0003). Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.

References

  1. Diabetes. 1994 Dec;43(12):1435-9 - PubMed
  2. Metabolism. 1997 Feb;46(2):192-8 - PubMed
  3. J Clin Invest. 1995 Feb;95(2):705-12 - PubMed
  4. JAMA. 1996 Sep 18;276(11):875-81 - PubMed
  5. JAMA. 1996 Sep 18;276(11):882-8 - PubMed
  6. Metabolism. 1990 Oct;39(10):1056-62 - PubMed
  7. JAMA. 1996 Sep 18;276(11):914-5 - PubMed

Publication Types